Histamine H3 receptor activation potentiates peripheral opioid-mediated antinociception: substance P role in peripheral inflammation in mice.
Opioids provide effective analgesia in adult patients with painful inflammatory diseases. The proposed mechanism of action is the activation of peripheral opioid receptors, which may be up-regulated in such conditions. Here, by using a chronic inflammation model, namely subplantar injection of Complete Freund's adjuvant, we show a peripheral synergistic interaction between the histamine H(3) receptor agonist R-(alpha)-methylhistamine and fentanyl on the inhibition of thermal hyperalgesia and of peripheral substance P accumulation. Firstly, dose-related effects obtained for the subplantar antinociceptive effect of fentanyl (0.05-1 microg) in the presence of a fixed dose of R-(alpha)-methylhistamine (12.5 microg) showed a shift to the left when compared to that obtained with fentanyl alone. In a similar way, the subcutaneous administration of fentanyl (0.005-0.1mg/kg) plus a fixed dose of R-(alpha)-methylhistamine (0.5mg/kg) induced a supra additive effect on the inhibition of substance P accumulation in the hind-paw skin of inflamed mice. Interestingly, when a neurokinin-1 receptor antagonist was co-administered, the antinociceptive effects of the combined treatment were potentiated. The peripheral adjuvant effect of R-(alpha)-methylhistamine on fentanyl antinociception and inhibition of substance P accumulation was also demonstrated by means of opioid and histamine H(3) receptors selective antagonists: first, naloxone blockade of fentanyl-mediated effects were partially reversed by co-administration of R-(alpha)-methylhistamine, and second, thioperamide partially antagonised the combined R-(alpha)-methylhistamine/fentanyl effects. Overall, our results clearly show that R-(alpha)-methylhistamine enhances fentanyl effects at peripheral sites, and that the control of substance P levels might be one of the mechanisms responsible of such interaction.
Fernández-Dueñas
Víctor
V
Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, Universitat de Barcelona, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. vfernandez@ub.edu
Ciruela
Francisco
F
Gandía
Jorge
J
Sánchez
Sílvia
S
Planas
Eulàlia
E
Poveda
Raquel
R
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005283:Fentanyl / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005620:Freund's Adjuvant; D017442:Histamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D006930:Hyperalgesia / Q000188:drug therapy; D007249:Inflammation / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D008761:Methylhistamines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051379:Mice; D009270:Naloxone / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy; D010880:Piperidines / Q000494:pharmacology; D018100:Receptors, Histamine H3 / Q000187:drug effects; D012867:Skin / Q000187:drug effects* / Q000378:metabolism; D013373:Substance P / Q000378:metabolism*
D000700:Analgesics; D017442:Histamine Agonists; D008761:Methylhistamines; D010880:Piperidines; D018100:Receptors, Histamine H3; D013373:Substance P; D009270:Naloxone; D005620:Freund's Adjuvant; C052075:thioperamide; D005283:Fentanyl